| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Grape Seed Extract | 14 | 2019 | 44 | 5.440 |
Why?
|
| Prostatic Neoplasms | 56 | 2024 | 1040 | 4.570 |
Why?
|
| Antineoplastic Agents, Phytogenic | 22 | 2019 | 191 | 3.970 |
Why?
|
| Apoptosis | 73 | 2020 | 2554 | 3.750 |
Why?
|
| Silymarin | 52 | 2016 | 199 | 3.610 |
Why?
|
| Vitis | 15 | 2013 | 42 | 3.490 |
Why?
|
| Plant Extracts | 19 | 2020 | 202 | 2.930 |
Why?
|
| Anthocyanins | 5 | 2019 | 33 | 2.250 |
Why?
|
| Seeds | 12 | 2013 | 86 | 2.080 |
Why?
|
| Anticarcinogenic Agents | 12 | 2014 | 77 | 2.050 |
Why?
|
| Cell Cycle | 24 | 2018 | 601 | 1.780 |
Why?
|
| Chemical Warfare Agents | 12 | 2025 | 114 | 1.540 |
Why?
|
| Mustard Gas | 12 | 2025 | 103 | 1.460 |
Why?
|
| Cell Proliferation | 39 | 2021 | 2476 | 1.440 |
Why?
|
| Cell Line, Tumor | 55 | 2019 | 3407 | 1.370 |
Why?
|
| Corneal Injuries | 7 | 2024 | 44 | 1.360 |
Why?
|
| Oxidative Stress | 14 | 2025 | 1317 | 1.350 |
Why?
|
| Biflavonoids | 3 | 2019 | 9 | 1.310 |
Why?
|
| Proanthocyanidins | 3 | 2019 | 10 | 1.310 |
Why?
|
| Catechin | 3 | 2019 | 24 | 1.280 |
Why?
|
| Colonic Neoplasms | 5 | 2014 | 258 | 1.250 |
Why?
|
| Colorectal Neoplasms | 10 | 2014 | 808 | 1.230 |
Why?
|
| NF-kappa B | 18 | 2016 | 692 | 1.190 |
Why?
|
| Gallic Acid | 4 | 2009 | 13 | 1.120 |
Why?
|
| DNA Damage | 16 | 2019 | 421 | 1.110 |
Why?
|
| Antineoplastic Agents | 16 | 2021 | 2127 | 1.010 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2017 | 197 | 0.980 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 7 | 2017 | 152 | 0.970 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 400 | 0.970 |
Why?
|
| Cell Survival | 26 | 2021 | 1120 | 0.950 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 6 | 2017 | 185 | 0.930 |
Why?
|
| Reactive Oxygen Species | 8 | 2017 | 624 | 0.920 |
Why?
|
| Signal Transduction | 29 | 2019 | 5084 | 0.870 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 11 | 2012 | 121 | 0.840 |
Why?
|
| Phytotherapy | 5 | 2009 | 83 | 0.820 |
Why?
|
| Mechlorethamine | 8 | 2024 | 60 | 0.810 |
Why?
|
| Skin | 15 | 2019 | 749 | 0.810 |
Why?
|
| Neovascularization, Pathologic | 10 | 2018 | 300 | 0.800 |
Why?
|
| Caspases | 12 | 2012 | 247 | 0.800 |
Why?
|
| Mitochondria | 7 | 2017 | 949 | 0.800 |
Why?
|
| Adenocarcinoma | 7 | 2022 | 935 | 0.780 |
Why?
|
| Neoplasm Proteins | 7 | 2014 | 432 | 0.780 |
Why?
|
| Tumor Cells, Cultured | 25 | 2021 | 957 | 0.770 |
Why?
|
| Cell Cycle Proteins | 18 | 2015 | 616 | 0.760 |
Why?
|
| Phytic Acid | 7 | 2010 | 42 | 0.760 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2019 | 528 | 0.750 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2014 | 645 | 0.750 |
Why?
|
| STAT3 Transcription Factor | 6 | 2013 | 206 | 0.730 |
Why?
|
| Prostate | 8 | 2024 | 175 | 0.720 |
Why?
|
| Mice, Nude | 24 | 2020 | 697 | 0.710 |
Why?
|
| Head and Neck Neoplasms | 4 | 2014 | 551 | 0.700 |
Why?
|
| Carcinoma | 6 | 2011 | 229 | 0.680 |
Why?
|
| Cell Movement | 9 | 2019 | 967 | 0.670 |
Why?
|
| Phosphorylation | 24 | 2019 | 1760 | 0.670 |
Why?
|
| Ultraviolet Rays | 11 | 2022 | 396 | 0.640 |
Why?
|
| Mice | 58 | 2024 | 17789 | 0.640 |
Why?
|
| Antioxidants | 17 | 2023 | 585 | 0.640 |
Why?
|
| Animals | 77 | 2025 | 36935 | 0.630 |
Why?
|
| MAP Kinase Signaling System | 8 | 2015 | 322 | 0.620 |
Why?
|
| Endoplasmic Reticulum Stress | 4 | 2014 | 110 | 0.620 |
Why?
|
| Azoxymethane | 3 | 2014 | 20 | 0.600 |
Why?
|
| Stilbenes | 4 | 2013 | 35 | 0.590 |
Why?
|
| Dexamethasone | 6 | 2025 | 370 | 0.570 |
Why?
|
| Cell Division | 16 | 2012 | 794 | 0.560 |
Why?
|
| Carcinogens | 3 | 2013 | 125 | 0.560 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2017 | 6 | 0.560 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2011 | 229 | 0.550 |
Why?
|
| Enzyme Activation | 16 | 2020 | 811 | 0.550 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2022 | 75 | 0.550 |
Why?
|
| Autophagy | 3 | 2014 | 284 | 0.540 |
Why?
|
| Caspase 3 | 10 | 2019 | 246 | 0.540 |
Why?
|
| Skin Neoplasms | 10 | 2022 | 855 | 0.540 |
Why?
|
| Integrins | 2 | 2015 | 95 | 0.540 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2013 | 254 | 0.520 |
Why?
|
| Endothelial Cells | 3 | 2015 | 785 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2021 | 2057 | 0.510 |
Why?
|
| Male | 78 | 2025 | 67801 | 0.500 |
Why?
|
| DNA-Binding Proteins | 12 | 2015 | 1501 | 0.490 |
Why?
|
| Cyclin-Dependent Kinases | 8 | 2007 | 132 | 0.490 |
Why?
|
| Cornea | 6 | 2024 | 138 | 0.480 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2016 | 173 | 0.470 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2017 | 313 | 0.470 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 328 | 0.470 |
Why?
|
| Electron Transport Complex III | 1 | 2014 | 16 | 0.460 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2015 | 107 | 0.450 |
Why?
|
| Humans | 108 | 2024 | 137624 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 85 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2019 | 327 | 0.440 |
Why?
|
| Cell Death | 8 | 2023 | 373 | 0.440 |
Why?
|
| Cyclooxygenase 2 | 10 | 2021 | 178 | 0.440 |
Why?
|
| Momordica charantia | 3 | 2020 | 15 | 0.430 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2013 | 10 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2017 | 437 | 0.430 |
Why?
|
| Rabbits | 10 | 2025 | 780 | 0.420 |
Why?
|
| Tongue Neoplasms | 1 | 2013 | 24 | 0.420 |
Why?
|
| Immunoblotting | 7 | 2017 | 308 | 0.420 |
Why?
|
| Arsenicals | 2 | 2023 | 30 | 0.410 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 30 | 0.400 |
Why?
|
| Adipocytes | 1 | 2014 | 222 | 0.390 |
Why?
|
| Blotting, Western | 14 | 2016 | 1228 | 0.390 |
Why?
|
| Receptors, Androgen | 1 | 2013 | 150 | 0.380 |
Why?
|
| Exosomes | 3 | 2020 | 103 | 0.380 |
Why?
|
| Enzyme Inhibitors | 8 | 2013 | 840 | 0.380 |
Why?
|
| Glucuronides | 1 | 2011 | 18 | 0.370 |
Why?
|
| Caspase 9 | 2 | 2013 | 57 | 0.360 |
Why?
|
| Up-Regulation | 5 | 2013 | 840 | 0.360 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2013 | 124 | 0.360 |
Why?
|
| Microsomes, Liver | 1 | 2011 | 86 | 0.360 |
Why?
|
| Poly(ADP-ribose) Polymerases | 9 | 2019 | 98 | 0.360 |
Why?
|
| Stress, Physiological | 1 | 2014 | 443 | 0.360 |
Why?
|
| Cadherins | 6 | 2018 | 206 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2008 | 38 | 0.340 |
Why?
|
| Irritants | 6 | 2024 | 43 | 0.340 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 9 | 2012 | 74 | 0.340 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2025 | 496 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2020 | 872 | 0.340 |
Why?
|
| Down-Regulation | 10 | 2014 | 656 | 0.330 |
Why?
|
| Transcription Factors | 9 | 2014 | 1720 | 0.330 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 4 | 2004 | 39 | 0.330 |
Why?
|
| Dietary Supplements | 3 | 2014 | 561 | 0.330 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 92 | 0.330 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2010 | 20 | 0.320 |
Why?
|
| Carcinogenesis | 3 | 2024 | 217 | 0.320 |
Why?
|
| Lung Neoplasms | 6 | 2014 | 2527 | 0.320 |
Why?
|
| Intestinal Polyps | 1 | 2010 | 17 | 0.320 |
Why?
|
| Transcription Factor AP-1 | 8 | 2016 | 91 | 0.320 |
Why?
|
| Oxidation-Reduction | 7 | 2018 | 1062 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2018 | 1392 | 0.310 |
Why?
|
| HT29 Cells | 5 | 2014 | 41 | 0.310 |
Why?
|
| Epithelium, Corneal | 3 | 2019 | 41 | 0.300 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 1730 | 0.300 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 937 | 0.300 |
Why?
|
| beta Catenin | 4 | 2013 | 253 | 0.300 |
Why?
|
| Epidermal Growth Factor | 4 | 2013 | 177 | 0.300 |
Why?
|
| Mice, Hairless | 12 | 2016 | 60 | 0.290 |
Why?
|
| Models, Biological | 4 | 2014 | 1782 | 0.280 |
Why?
|
| Antidotes | 3 | 2015 | 143 | 0.280 |
Why?
|
| Colon | 1 | 2010 | 282 | 0.280 |
Why?
|
| Cyclin D1 | 7 | 2019 | 68 | 0.270 |
Why?
|
| Tannins | 1 | 2007 | 5 | 0.270 |
Why?
|
| Cyclins | 7 | 2007 | 91 | 0.270 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2013 | 196 | 0.270 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2024 | 18 | 0.260 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2021 | 193 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 800 | 0.260 |
Why?
|
| Proteomics | 5 | 2024 | 1110 | 0.260 |
Why?
|
| MicroRNAs | 1 | 2013 | 690 | 0.250 |
Why?
|
| Serine Endopeptidases | 2 | 2024 | 123 | 0.250 |
Why?
|
| Anoikis | 1 | 2006 | 31 | 0.250 |
Why?
|
| Spheroids, Cellular | 2 | 2019 | 77 | 0.250 |
Why?
|
| Androgens | 3 | 2018 | 187 | 0.250 |
Why?
|
| Inflammation | 8 | 2025 | 2838 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 7 | 2020 | 509 | 0.240 |
Why?
|
| Fibroblasts | 4 | 2016 | 995 | 0.240 |
Why?
|
| G1 Phase | 7 | 2009 | 71 | 0.230 |
Why?
|
| Cytochromes c | 4 | 2013 | 60 | 0.230 |
Why?
|
| HCT116 Cells | 3 | 2014 | 80 | 0.230 |
Why?
|
| Limbus Corneae | 1 | 2025 | 8 | 0.230 |
Why?
|
| DNA Repair | 3 | 2015 | 231 | 0.220 |
Why?
|
| Naproxen | 1 | 2024 | 17 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2005 | 646 | 0.220 |
Why?
|
| Oncogene Fusion | 1 | 2024 | 13 | 0.220 |
Why?
|
| Intracellular Membranes | 2 | 2004 | 84 | 0.210 |
Why?
|
| Patched-1 Receptor | 2 | 2022 | 16 | 0.200 |
Why?
|
| Pentacyclic Triterpenes | 2 | 2014 | 15 | 0.200 |
Why?
|
| ErbB Receptors | 3 | 2017 | 612 | 0.200 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2003 | 45 | 0.200 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 44 | 0.200 |
Why?
|
| Structure-Activity Relationship | 5 | 2021 | 570 | 0.200 |
Why?
|
| Keratinocytes | 3 | 2014 | 249 | 0.190 |
Why?
|
| Cell Hypoxia | 4 | 2016 | 226 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 351 | 0.190 |
Why?
|
| CDC2 Protein Kinase | 4 | 2006 | 31 | 0.190 |
Why?
|
| Cytokines | 5 | 2024 | 2085 | 0.190 |
Why?
|
| Deoxycytidine | 2 | 2020 | 179 | 0.180 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2021 | 15 | 0.180 |
Why?
|
| Intestine, Small | 2 | 2014 | 156 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2016 | 545 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 5 | 2010 | 66 | 0.180 |
Why?
|
| Proliferating Cell Nuclear Antigen | 4 | 2010 | 52 | 0.180 |
Why?
|
| Histones | 8 | 2019 | 637 | 0.170 |
Why?
|
| Molecular Structure | 4 | 2021 | 489 | 0.170 |
Why?
|
| Curcumin | 1 | 2021 | 29 | 0.170 |
Why?
|
| Lung | 1 | 2014 | 4060 | 0.170 |
Why?
|
| Aspirin | 1 | 2024 | 387 | 0.170 |
Why?
|
| Stem Cells | 1 | 2025 | 594 | 0.170 |
Why?
|
| Transplantation, Heterologous | 5 | 2009 | 194 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 6 | 2016 | 5764 | 0.160 |
Why?
|
| Hedgehog Proteins | 2 | 2022 | 195 | 0.160 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2019 | 23 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 429 | 0.160 |
Why?
|
| Administration, Oral | 5 | 2011 | 817 | 0.160 |
Why?
|
| Protein Carbonylation | 1 | 2019 | 54 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2013 | 1083 | 0.160 |
Why?
|
| Pesticides | 1 | 2019 | 62 | 0.150 |
Why?
|
| Jagged-1 Protein | 1 | 2019 | 23 | 0.150 |
Why?
|
| Matrix Metalloproteinases | 1 | 2020 | 95 | 0.150 |
Why?
|
| Dimerization | 2 | 2011 | 199 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1263 | 0.150 |
Why?
|
| Retinoblastoma Protein | 3 | 2004 | 56 | 0.150 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2019 | 69 | 0.150 |
Why?
|
| Acetylcysteine | 4 | 2023 | 145 | 0.150 |
Why?
|
| Immunoenzyme Techniques | 4 | 2013 | 218 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 64 | 0.150 |
Why?
|
| Protein Kinases | 3 | 2013 | 319 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2016 | 278 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 3 | 2006 | 29 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2015 | 56 | 0.140 |
Why?
|
| Glycoconjugates | 1 | 2018 | 7 | 0.140 |
Why?
|
| Cell Line | 9 | 2015 | 2845 | 0.140 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 2166 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2009 | 455 | 0.140 |
Why?
|
| Mast Cells | 1 | 2019 | 148 | 0.140 |
Why?
|
| Cells, Cultured | 9 | 2019 | 4193 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 708 | 0.140 |
Why?
|
| Epithelial Cells | 4 | 2019 | 1097 | 0.140 |
Why?
|
| Energy Metabolism | 2 | 2014 | 922 | 0.130 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 2 | 2018 | 10 | 0.130 |
Why?
|
| Organophosphates | 1 | 2018 | 134 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 289 | 0.130 |
Why?
|
| Asphyxia Neonatorum | 1 | 1997 | 17 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 3 | 2011 | 72 | 0.130 |
Why?
|
| Growth Hormone | 1 | 1997 | 101 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2014 | 465 | 0.130 |
Why?
|
| HIV | 1 | 2018 | 234 | 0.130 |
Why?
|
| Proteome | 2 | 2019 | 472 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2014 | 98 | 0.130 |
Why?
|
| cdc25 Phosphatases | 2 | 2006 | 15 | 0.130 |
Why?
|
| Lipogenesis | 1 | 2016 | 61 | 0.120 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 18 | 0.120 |
Why?
|
| Chromatography, Liquid | 3 | 2024 | 433 | 0.120 |
Why?
|
| Corneal Neovascularization | 1 | 2016 | 15 | 0.120 |
Why?
|
| Interleukin-4 | 2 | 2014 | 216 | 0.120 |
Why?
|
| Corneal Stroma | 1 | 2016 | 23 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 4287 | 0.120 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 180 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 115 | 0.120 |
Why?
|
| Flavones | 2 | 2006 | 10 | 0.120 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 88 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2021 | 132 | 0.120 |
Why?
|
| Microscopy, Confocal | 5 | 2015 | 325 | 0.120 |
Why?
|
| Biomarkers | 3 | 2022 | 4155 | 0.120 |
Why?
|
| Hematopoietic System | 1 | 2014 | 8 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 413 | 0.110 |
Why?
|
| I-kappa B Kinase | 3 | 2003 | 55 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2024 | 532 | 0.110 |
Why?
|
| Kinetics | 3 | 2014 | 1669 | 0.110 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 39 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 208 | 0.110 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 58 | 0.110 |
Why?
|
| Cytoplasm | 2 | 2013 | 274 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 1243 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2013 | 209 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2014 | 26 | 0.110 |
Why?
|
| Fibronectins | 1 | 2014 | 133 | 0.110 |
Why?
|
| Adherens Junctions | 1 | 2013 | 25 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 390 | 0.110 |
Why?
|
| Peptide Mapping | 1 | 2014 | 64 | 0.110 |
Why?
|
| G2 Phase | 2 | 2012 | 38 | 0.110 |
Why?
|
| Inflammation Mediators | 3 | 2024 | 513 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 2 | 4 | 2012 | 39 | 0.100 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2014 | 36 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2012 | 47 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2014 | 103 | 0.100 |
Why?
|
| Metabolomics | 2 | 2016 | 679 | 0.100 |
Why?
|
| CDC2-CDC28 Kinases | 2 | 2004 | 18 | 0.100 |
Why?
|
| Mice, Inbred A | 1 | 2013 | 49 | 0.100 |
Why?
|
| Tongue | 1 | 2013 | 80 | 0.100 |
Why?
|
| Mice, Inbred Strains | 1 | 2014 | 409 | 0.100 |
Why?
|
| Momordica | 1 | 2013 | 2 | 0.100 |
Why?
|
| Protein Stability | 1 | 2014 | 176 | 0.100 |
Why?
|
| Extracellular Vesicles | 1 | 2015 | 146 | 0.100 |
Why?
|
| Doxorubicin | 3 | 2004 | 363 | 0.100 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2013 | 15 | 0.100 |
Why?
|
| Methionine | 1 | 2014 | 160 | 0.100 |
Why?
|
| Triglycerides | 1 | 2015 | 525 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 655 | 0.100 |
Why?
|
| RANK Ligand | 1 | 2012 | 29 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 72 | 0.100 |
Why?
|
| Time Factors | 7 | 2015 | 6831 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2012 | 72 | 0.100 |
Why?
|
| Protein Biosynthesis | 2 | 2013 | 433 | 0.100 |
Why?
|
| Superoxides | 1 | 2013 | 202 | 0.100 |
Why?
|
| Comfrey | 1 | 2012 | 2 | 0.100 |
Why?
|
| Spleen | 1 | 2014 | 514 | 0.100 |
Why?
|
| Osteoclasts | 1 | 2012 | 52 | 0.100 |
Why?
|
| Glyceric Acids | 1 | 2012 | 6 | 0.100 |
Why?
|
| I-kappa B Proteins | 2 | 2003 | 81 | 0.100 |
Why?
|
| Flavonolignans | 1 | 2012 | 10 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2013 | 121 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 170 | 0.100 |
Why?
|
| Infant, Premature | 1 | 1997 | 574 | 0.100 |
Why?
|
| NFATC Transcription Factors | 1 | 2012 | 95 | 0.090 |
Why?
|
| Corneal Diseases | 1 | 2012 | 35 | 0.090 |
Why?
|
| Doxycycline | 1 | 2012 | 62 | 0.090 |
Why?
|
| Flavonoids | 2 | 2003 | 85 | 0.090 |
Why?
|
| Glutathione | 2 | 2011 | 357 | 0.090 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2012 | 20 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2018 | 744 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 676 | 0.090 |
Why?
|
| Photosensitizing Agents | 1 | 2012 | 38 | 0.090 |
Why?
|
| Janus Kinase 1 | 2 | 2011 | 24 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 38 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 365 | 0.090 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2019 | 162 | 0.090 |
Why?
|
| Disease Progression | 3 | 2008 | 2753 | 0.090 |
Why?
|
| Methylation | 1 | 2011 | 229 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 765 | 0.090 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 661 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2014 | 347 | 0.090 |
Why?
|
| Oxygen | 1 | 2015 | 938 | 0.080 |
Why?
|
| Cell Differentiation | 6 | 2014 | 1993 | 0.080 |
Why?
|
| Epidermis | 2 | 2013 | 157 | 0.080 |
Why?
|
| Phenotype | 1 | 2019 | 3200 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 853 | 0.080 |
Why?
|
| Lactoferrin | 1 | 2010 | 31 | 0.080 |
Why?
|
| Transfection | 4 | 2014 | 945 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2014 | 778 | 0.080 |
Why?
|
| Rats, Inbred F344 | 1 | 2010 | 264 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2008 | 2834 | 0.080 |
Why?
|
| DNA Primers | 1 | 2011 | 514 | 0.080 |
Why?
|
| Hepatitis | 1 | 2010 | 48 | 0.080 |
Why?
|
| Dermatitis, Irritant | 1 | 2009 | 10 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 298 | 0.080 |
Why?
|
| Macrophages | 2 | 2019 | 1550 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2015 | 134 | 0.080 |
Why?
|
| Peptides | 1 | 2015 | 985 | 0.080 |
Why?
|
| Neoplasm Transplantation | 3 | 2004 | 253 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 233 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 139 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2010 | 137 | 0.070 |
Why?
|
| Membrane Potentials | 3 | 2005 | 285 | 0.070 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 622 | 0.070 |
Why?
|
| Metformin | 1 | 2012 | 331 | 0.070 |
Why?
|
| Butylhydroxybutylnitrosamine | 1 | 2007 | 6 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2011 | 789 | 0.070 |
Why?
|
| Autocrine Communication | 1 | 2008 | 41 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 927 | 0.070 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 57 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 341 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1061 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 366 | 0.070 |
Why?
|
| Laminin | 2 | 2005 | 72 | 0.070 |
Why?
|
| Lipid Peroxidation | 2 | 2019 | 153 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 32 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 2181 | 0.070 |
Why?
|
| ets-Domain Protein Elk-1 | 2 | 2005 | 12 | 0.070 |
Why?
|
| Glioma | 1 | 2011 | 395 | 0.070 |
Why?
|
| Proteoglycans | 2 | 2005 | 107 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 1475 | 0.060 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2004 | 71 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2003 | 54 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 972 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2607 | 0.060 |
Why?
|
| Caspase 2 | 1 | 2006 | 13 | 0.060 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2006 | 4 | 0.060 |
Why?
|
| Hypoxia | 1 | 2013 | 1112 | 0.060 |
Why?
|
| Proteins | 2 | 2003 | 1009 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2005 | 343 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2006 | 31 | 0.060 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 26 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 188 | 0.060 |
Why?
|
| DNA | 3 | 2010 | 1460 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1768 | 0.060 |
Why?
|
| Female | 13 | 2022 | 73366 | 0.060 |
Why?
|
| Drug Synergism | 3 | 2013 | 381 | 0.060 |
Why?
|
| S Phase | 1 | 2005 | 77 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1240 | 0.060 |
Why?
|
| Benzopyrans | 1 | 2005 | 26 | 0.060 |
Why?
|
| Collagen | 2 | 2005 | 452 | 0.060 |
Why?
|
| Rad51 Recombinase | 2 | 2015 | 15 | 0.060 |
Why?
|
| Administration, Cutaneous | 2 | 2015 | 130 | 0.060 |
Why?
|
| Glycosides | 1 | 2005 | 36 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 55 | 0.060 |
Why?
|
| Tyrosine | 1 | 2005 | 222 | 0.060 |
Why?
|
| Butyrates | 1 | 2005 | 61 | 0.050 |
Why?
|
| Deoxyguanosine | 2 | 2015 | 25 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2004 | 92 | 0.050 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 110 | 0.050 |
Why?
|
| Densitometry | 1 | 2003 | 37 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 597 | 0.050 |
Why?
|
| Carboplatin | 1 | 2004 | 144 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2023 | 59 | 0.050 |
Why?
|
| Rats | 2 | 2010 | 5646 | 0.050 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 52 | 0.050 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2003 | 12 | 0.050 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2003 | 12 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 48 | 0.050 |
Why?
|
| Cell-Free System | 1 | 2003 | 53 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2024 | 176 | 0.050 |
Why?
|
| Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
|
| Comet Assay | 2 | 2014 | 16 | 0.050 |
Why?
|
| Anthracenes | 1 | 2003 | 31 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 125 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2003 | 75 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 167 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 1091 | 0.050 |
Why?
|
| Peroxidase | 2 | 2015 | 175 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2003 | 148 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 362 | 0.050 |
Why?
|
| Corneal Keratocytes | 1 | 2021 | 9 | 0.050 |
Why?
|
| Cisplatin | 1 | 2004 | 320 | 0.050 |
Why?
|
| Ligands | 1 | 2024 | 664 | 0.050 |
Why?
|
| Actins | 1 | 2024 | 416 | 0.040 |
Why?
|
| Flow Cytometry | 4 | 2010 | 1193 | 0.040 |
Why?
|
| Liver | 1 | 2010 | 1943 | 0.040 |
Why?
|
| Bromodeoxyuridine | 3 | 2007 | 79 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2021 | 268 | 0.040 |
Why?
|
| Chromones | 2 | 2014 | 44 | 0.040 |
Why?
|
| Aldehydes | 2 | 2012 | 145 | 0.040 |
Why?
|
| Tumor Hypoxia | 1 | 2020 | 7 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 215 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 95 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2021 | 187 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 64 | 0.040 |
Why?
|
| Morpholines | 2 | 2014 | 122 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2002 | 338 | 0.040 |
Why?
|
| Cyclin E | 2 | 2012 | 25 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 787 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2010 | 161 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 564 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 671 | 0.040 |
Why?
|
| Cytosol | 2 | 2013 | 227 | 0.040 |
Why?
|
| Filamins | 1 | 2019 | 28 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1503 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 92 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 56 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2016 | 3018 | 0.040 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2018 | 11 | 0.040 |
Why?
|
| CD24 Antigen | 1 | 2018 | 20 | 0.040 |
Why?
|
| Cell Nucleus | 3 | 2007 | 620 | 0.040 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 1689 | 0.040 |
Why?
|
| E2F Transcription Factors | 3 | 2003 | 60 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2012 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 65 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2018 | 102 | 0.030 |
Why?
|
| Protein Transport | 2 | 2011 | 446 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1272 | 0.030 |
Why?
|
| NADPH Oxidase 1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Annonaceae | 1 | 2016 | 4 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 39 | 0.030 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2015 | 5 | 0.030 |
Why?
|
| Diet | 1 | 2004 | 1279 | 0.030 |
Why?
|
| Body Weight | 2 | 2014 | 985 | 0.030 |
Why?
|
| Dermis | 1 | 2015 | 33 | 0.030 |
Why?
|
| Rupture | 1 | 2016 | 92 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 156 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2016 | 113 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2015 | 12 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1125 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 35 | 0.030 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1997 | 327 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 98 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2005 | 49 | 0.030 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Neoplasms | 1 | 2009 | 2661 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 44 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 17 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 111 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 123 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2015 | 145 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 145 | 0.030 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2014 | 51 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 246 | 0.030 |
Why?
|
| Boron Compounds | 1 | 2014 | 27 | 0.030 |
Why?
|
| Tetraspanins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 331 | 0.030 |
Why?
|
| Annexin A2 | 1 | 2013 | 16 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 282 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1997 | 1314 | 0.030 |
Why?
|
| Metalloproteases | 1 | 2013 | 43 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 477 | 0.030 |
Why?
|
| Protein Binding | 2 | 2015 | 2225 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 135 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 500 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 307 | 0.030 |
Why?
|
| Mitosis | 2 | 2006 | 192 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2013 | 24 | 0.030 |
Why?
|
| Somatomedins | 1 | 2013 | 27 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 239 | 0.030 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 26 | 0.030 |
Why?
|
| Growth Inhibitors | 2 | 2003 | 43 | 0.030 |
Why?
|
| Vacuoles | 1 | 2013 | 40 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 523 | 0.030 |
Why?
|
| Cell Shape | 1 | 2013 | 57 | 0.020 |
Why?
|
| Mitogens | 1 | 2013 | 61 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 142 | 0.020 |
Why?
|
| Annexin A5 | 2 | 2002 | 25 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 328 | 0.020 |
Why?
|
| Cyclin B1 | 1 | 2012 | 6 | 0.020 |
Why?
|
| E2F4 Transcription Factor | 2 | 2003 | 8 | 0.020 |
Why?
|
| Macrolides | 1 | 2013 | 67 | 0.020 |
Why?
|
| Calcium | 1 | 2019 | 1200 | 0.020 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2012 | 2 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 86 | 0.020 |
Why?
|
| E2F3 Transcription Factor | 2 | 2002 | 10 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2012 | 15 | 0.020 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2011 | 4 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 654 | 0.020 |
Why?
|
| Pyrimidine Dimers | 1 | 2011 | 6 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 194 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2012 | 31 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 42 | 0.020 |
Why?
|
| Azacitidine | 1 | 2013 | 140 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 140 | 0.020 |
Why?
|
| Chromans | 1 | 2011 | 25 | 0.020 |
Why?
|
| Acetylation | 1 | 2012 | 248 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 706 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 60 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 410 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1315 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2249 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 73 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 518 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2011 | 76 | 0.020 |
Why?
|
| Buthionine Sulfoximine | 1 | 2010 | 10 | 0.020 |
Why?
|
| Adenine | 1 | 2013 | 271 | 0.020 |
Why?
|
| Pyridines | 1 | 2014 | 504 | 0.020 |
Why?
|
| Dermatitis | 1 | 2010 | 20 | 0.020 |
Why?
|
| Skinfold Thickness | 1 | 2010 | 46 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 92 | 0.020 |
Why?
|
| Genes, APC | 1 | 2010 | 12 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 528 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2010 | 76 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 8 | 1 | 2010 | 43 | 0.020 |
Why?
|
| Deoxyadenosines | 1 | 2009 | 9 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 469 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2010 | 55 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2009 | 24 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 411 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1590 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 29 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2012 | 265 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 1067 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2010 | 133 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 143 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 506 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 185 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 353 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1997 | 3567 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 304 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 204 | 0.020 |
Why?
|
| Fruit | 1 | 2009 | 140 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2009 | 193 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 202 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 330 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 119 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 319 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 151 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 378 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 155 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 985 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 156 | 0.020 |
Why?
|
| Toluene | 1 | 2006 | 13 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2006 | 32 | 0.020 |
Why?
|
| Cyclin D3 | 1 | 2005 | 5 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 2005 | 20 | 0.010 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 30 | 0.010 |
Why?
|
| Ribonucleotide Reductases | 1 | 2005 | 31 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1997 | 6084 | 0.010 |
Why?
|
| Chrysanthemum | 1 | 2005 | 2 | 0.010 |
Why?
|
| Rhamnose | 1 | 2005 | 3 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 72 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2004 | 55 | 0.010 |
Why?
|
| Plant Oils | 1 | 2004 | 31 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 82 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 81 | 0.010 |
Why?
|
| Biological Assay | 1 | 2005 | 124 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2004 | 151 | 0.010 |
Why?
|
| Papilloma | 1 | 2003 | 51 | 0.010 |
Why?
|
| Animal Feed | 1 | 2004 | 53 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2003 | 52 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 110 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2004 | 115 | 0.010 |
Why?
|
| Propidium | 1 | 2002 | 8 | 0.010 |
Why?
|
| Trypan Blue | 1 | 2002 | 6 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 1251 | 0.010 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2005 | 340 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 86 | 0.010 |
Why?
|
| E2F2 Transcription Factor | 1 | 2002 | 15 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 100 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2002 | 2 | 0.010 |
Why?
|
| E2F5 Transcription Factor | 1 | 2002 | 3 | 0.010 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2002 | 4 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 2002 | 64 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 1809 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 10823 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 124 | 0.010 |
Why?
|
| Serine | 1 | 2002 | 141 | 0.010 |
Why?
|
| Cell Separation | 1 | 2002 | 319 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 770 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 3956 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 916 | 0.010 |
Why?
|